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Summary
The generation of lipoxygenase products of arachidonic acid is considered an important event
in inflammation . This study demonstrates the levels of both lipoxins and leukotrienes (LTC4,
LTD4, LTB4, and w-oxidized LTB4) generated from endogenous sources of arachidonate byPMN
primed with recombinant human granulocyte/macrophage colony-stimulating factor and in
coincubations with platelets (1:1 to 1:100 ratio) . Upon exposure to receptor-mediated stimuli
(FMLP and thrombin), the levels of lipoxins generated were within the range of both LTB4
and LTC4. Co-incubation of [1-14C]arachidonate-labeled platelets with primed polymorpho-
nuclear leukocytes (PMN) followed by addition of thrombin and FMLP led to the formation
of both 5- and 15-LO products that carried 14C label . Thus, in addition to the transcellular
conversion of LTA4 to platelet-derived lipoxins and LTC4, PMN can use platelet-derived ara-
chidonate to generate lipoxygenase products . These results are the first to document the relationship
between the levels oflipoxins and leukotrienes generated by receptor-mediated activation ofcytokknn-
primed PMN interacting with platelets. Moreover, they indicate that PMN-platelet interactions
utilize bidirectional transcellular routes to contribute to lipoxin formation .
T
he generation of eicosanoids by lipoxygenase-catalyzed
reactions is associated with the activation ofa wide range
ofhuman cell types that are involved in both physiologic and
pathophysiologic events (1) . It is now recognized that cell-cell
interactions can initiate transcellular pathways for the bio-
synthesis of lipoxygenase products (2) . These transcellular
pathways may not only serve to amplify the levels of eicosa-
noids within a local milieu but may also lead to the genera-
tion of biologically active metabolites with functions different
from those in its cell of origin. Studies on the interactions
betweenhuman platelets and leukocytes have revealed several
mechanistic models for transcellular eicosanoid biosynthesis,
which may also be operative within other tissues (2-8) .
Platelets, for example, can utilize leukocyte-derived leuko-
triene A4 to generate both peptido-leukotrienes (5, 6) and
lipoxins (7, 8) .
The ionophore of divalent cations A23187 is a useful tool
in examining the cellular biosynthesis of eicosanoids, and in
particular, transcellular pathways of formation because it (a)
is not cell type specific in its actions, which enables activa-
tion of combined cell types and (b) it provokes the formation
of individual eicosanoids inamounts that facilitate their iso-
lation and structural elucidation by physical methods (1-7).
By virtue of its ability to translocate divalent cations across
cell membranes, it initiates a variety of responses that require
an elevation in the intracellular levels of Cal+ . In this regard,
when added to human neutrophils and platelets, A23187 ac-
tivates both the release of arachidonic acid from endogenous
stores and lipoxygenation, which are two limiting events in
the biosynthesis oflipoxygenase products by these cells (1-8) .
Since A23187 activates cells by circumventing receptor-ligand
interactions in both cell types, potential regulatory events be-
tween individual lipoxygenases which may be operative fol-
lowing receptor activation remain to be fully appreciated .
Previous studies have shown that platelet-directed stimuli (i .e.,
thrombin) can initiate metabolic interactions between platelets
and neutrophils (4) . Thus, receptor-mediated activation of
combined cell types may lead to both quantitative and qualita-
tive differences in the profiles and individual eicosanoids gener-
ated by transcellular biosynthesis. Recent results haveshown
thatPMN primed by the cytokine granulocyte/macrophage
colony-stimulating factor (GM-CSF)t can generate LTB4 and
' Abbreviations used in this paper . DNCB, 2,4-dinitro-l-chlorobenzene; ED,
electrochemical detector ; GC, gas chromatography; GM-CSF, gran-
ulocyte/macrophage colony-stimulating factor ; LO, lipoxygenase ; LT,
leukotriene; MS, mass spectrometry; NICI, negativeion chemical ionization .
This work was presented in part at the 7th International Conference
on Prostaglandins and Related Compounds, Florence, May 1990.
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ulation by either the complement component (C5a) or the
chemoattractant (FMLP), in quantities that are detectable by
UVRP-HPLC (9, 10) . The enhanced levels of LTB4 gener-
ated by stimulated PMN primed with GM-CSF observed in
these studies are believed to be the result of increased avail-
ability of unesterified arachidonic acid generated during
priming of thePMN (9, 10) . Co-incubations ofplatelets and
PMN stimulated with thrombin and FMLP lead to lipoxin
generation without addition of substrates (8) . To gain in-
sight into the relationship between leukotrienes and lipoxins
generated by receptor-mediated signals, we have determined
the levels formed during co-incubations ofplatelets withGM-
CSF-primed PMN and have examined their routes of for-
mation .
Materials and Methods
FMLP, glutathione, and nitroprusside were from Sigma Chem-
ical Co . (St . Louis, MO) . DNCB and methyl formate were from
Eastman Kodak Co. (Rochester, NY) . Thrombin and LSM were
from Enzyme Research Laboratories, Inc . (South Bend, IN) and
Organon Teknika (Durham, NC), respectively . Human recombinant
GM-CSF was purchased from GenzymeCo. (Boston, MA) . Syn-
thetic eicosanoids used as reference materials were purchased from
Biomol Research Labs, Inc. (Philadelphia, PA) and [1-'4C]arachi-
donic acid was from New England Nuclear' (Boston, MA) .
Preparation of Cell Suspensions .
￿
For each experiment, fresh pe-
ripheral blood was obtained from healthy donorswho had not taken
aspirin or other medications for at least 7 d. When either platelets
alone, or both platelets and PMN were isolated, acid citrate dex-
trose was used as anticoagulant and the isolation begun by first
obtaining platelet-rich plasma from the whole blood (2) . Washed
platelets were prepared from PRP as described (2) and enumerated
using a Coulter Counter modelZM (Coulter Electronics, Inc., Hi-
aleah, FL) . Platelets were adjusted to 3 x 10' cells/ml before co-
incubation withPMN . Platelets were labeled (2) with 0.2 uCi/ml
of [1-"C]arachidonate . PMN were isolated from the remaining
blood by Ficoll-Hypaque gradient centrifugation and dextran
sedimentation. These suspensions contained 98 ± 1% PMN as
scored by light microscopy before incubations with GM-CSF.
Analysis ofLipoxins and Leukotrienes.
￿
All incubations were ter-
minated by addition of cold methanol (2 vol) containing PGB2 as
internal standard and extracted (8) . After elution from C18-Sep
Pack (Waters Associates, Milford, MA), materials within the methyl
formate fractions (i .e., LTB4, LXA4) were concentrated and chro-
matographed separately by RP-HPLC from materials and eluting
within the methanol fractions (i .e ., LTC4 and LTD4) . The w-oxi-
dation products of LTB4, LTB4, and the lipoxins were resolved
utilizing ED-UV detection with RP-HPLC (11-13) . This system
was equipped with both a Lambda Max UV detector model 481
and an on-line Electro Chemical detector (ED) modelM 460 oper-
ated with a Ag/AgC12 reference electrode (Waters Associates) . The
column, a Beckman Ultrasphere-ODS (4.5 mm x 25 cm) was
eluted with McOH/H20 (65:35, vol/vol), trifluoroacetic acid (1
mM) with a flow rate of 1 ml/min . This system permits detection
of lipoxins and leukotrienes in the picogram range (11, 12) . The
electrode potential was set at 1.345 V and the UV detector was
set at 270nm (to monitor leukotrienes) and 300nm (for lipoxins) .
Peptidoleukotrienes (LTC4, LTD4, and LTE4) were resolved using
an RPHPLC system equipped with an LC-75 UV detector (Perkin-
1452 Platelet and Cytokine-primed Neutrophil Interactions
Elmer, Norwalk, CT) and a pump model 110A (Beckman Instru-
ments, Berkeley,CA). The column was an Altar Ultrasphere-ODS
eluted with McOH/H20/acetic acid (65:35:0.01, vol/vol/vol) and
adjusted to pH 5.7 as mobile phase. Mono-HETEs (5-, 12-, 15-
HETE) were resolved using another separate RPHPLC system that
used an isocratic mobile phase of McOH/H20/acetic acid (75 :
25 :0.01, (vol/vol/vol) with theUV detector set at 235nm . Lipox-
ygenase products were routinely identified by comparison of their
individual retention times with those obtained for synthetic stan-
dards in each HPLC system . Their quantities were determined by
comparing peak areas obtained for calibrated standards in eachHPLC
system and the corresponding products from individual incubations
following correction for the recovery of internal standard .
Pentafluorobenzyl (PFB) ester trimethysilyl (TMS)-ether deriv-
atives of the materials which coeluted with LXA4 and LXB4 on
HPLC were collected and prepared as described (14, 15) . The PFB
ester derivatives were converted to their respective (TMS) deriva-
tive with bis (TMS) trifluoroacetamide (BSTFA)/pyridine (1:1) (15)
and analyzed by gas chromatography-mass spectrometry. The gas
chromatography-mass spectrometry (GC-MS) (Hewlett-Packard
model 5988A equipped with an HP 59970 workstation) was oper-
ated in the negative ion mode. Negative ion chemical ionization
(NICI) spectra were recorded with an electron energy of 377 eM
volts and a relative resulting voltage of 2,677 .
Results and Discussion
GM-CSF-primedPMN. GM-CSFrh-primedPMN exposed
to FMLP (10-7 M) generated both leukotrienes and lipoxins
without the addition of exogenous substrates (Table 1) . PMN
were exposed toGM-CSFrh for 90 min at 37°C before addi-
tion ofFMLP in the present experiments since previous results
have shown that, maximal priming occurs between 1 and 2 h
(9, 10). The present results with LTB4 and its w-oxidation
products, namely their quantities amounting to major prod-
ucts generatedbyGM-CSFrh-primed PMN exposed toFMLP
in vitro, are consistent with those recently reported (9, 10) .
Peptidoleukotrienes (LTC4, LTD4, and LTE4) were not de-
tected in these incubations, while the levels ofLXA4, LXB4,
and their all-trans-isomers were obtained in the range of
amounts similar to those observed for native LTB4 . The av-
erage sum of the lipoxins was within the same order of mag-
nitude as the sum obtained for LTB4 and its w-oxidation
products generated by GM-CSF-primed PMN . The levels
of lipoxins obtained here and their relationship to LTB4
production with GM-CSF-primed PMN stimulated via a
receptor-mediated agonist (i .e ., FMLP) are drastically different
from their relationship in ionophore-stimulated (A2s187) cells.
In the case of the ionophore A23t87, which bypass receptor
activation, PMN generate LTB4 as a dominant product and
LXA4 is generated in amounts 50-100 times less than LTB4
(13) . Therefore the present observation indicates that receptor-
mediated formation of lipoxygenase products by humanPMN
leads to a different balance between leukotrienes and lipoxins
than that observed with ionophore-stimulated cells.
As is the case with other eicosanoids, identification of the
lipoxins by GC-MS operated in the electron impact mode
requires isolation of materials in the microgram range (1) .
In contrast, analysis based upon GC-NICI MS has provento be a highly specific and sensitive methodology to deter-
mine trace amounts (picogram) of eicosanoids present in bi-
ological samples (14, 15). Since both ED and UV detection
with HPLC indicated that the lipoxins were formed in nano-
gram amounts (Table 1), it was necessary to use NICI-MS
to confirm the identity of the materials generated by GM-
CSF-primedPMN stimulated with FMLP that coeluted with
synthetic lipoxins on ED-UVRP-HPLC . To this end, the
materials beneath the UV peaks (on RP-HPLC before ED)
were collected, converted to PFB ester derivatives, treated with
BSTFA (14, 15), and analyzed by NICI-MS. The.mass spec-
trum of the PFB ester, TMS ether derivative of the material
which coeluted with LXA4 in RRHPLC, showed an intense
anion at m/e 567, which corresponded to the fragment
[M-PFB] - . Also present in its spectrum were ions at m/e
477 andm/e 387, corresponding to the loss ofTMSOH and
2(TMSOH) from the parent anion [M-PFB]' . There two
ions were present in <5% of the spectrum (m/e 50-600),
and the ion atm/e 567 was the base peak . Similarly, thePFB
ester, TMS ether derivatives obtained from isolated materials
that coeluted with LXB4, and the all-trans-isomers on RP-
HPLC also coeluted on GC with their respective PFB ester,
TMS ether derivatives prepared from synthetic lipoxins. In
each case, m/z 567 corresponding to [M-PFB] - was the base
peak in the spectrum (Brezinski, D., andC.N . Serhan, manu-
script submitted for publication) . Taken together, the physical
characteristics ofthese products onED-UVRP-HPLC as well
as ions present in their respective mass spectra recorded on
GC-NICI-MS suggest that primed PMN stimulated with FMLP




Coincubation ofGM-CSFrh Primed PMN and Platelets.
Simultaneous activation ofPMN and platelets in suspension
(1:10 cell ratio) with thrombin and FMLP leads to the for-
mation of both LXA4 and LXB4 (8) . In addition, evidence
has been presented indicating that platelet 12-LO and its
w-6-oxygenase activity can play a role in the formation of
lipoxins from PMN-derived leukotriene A4 (7, 8) . Since
platelets can also utilize LTA4 to generate LTC4 (5, 6), we
next evaluated the relationship between leukotrienes and
lipoxins generated by GM-CSFrh-primedPMN coincubated
with platelets (1:100 cell ratio) . After addition of FMLP
(10 -7 M), the peptido-LTs (LTC4, LTD4 , and LTE4) were
generated (Table 1). A 60% increase in w-oxidized LTB4 was
also noted with PMN stimulated in the presence ofplatelets.
Human platelets do not possess either the 5-lipoxygenase or
the co-oxidation system for LTB4 (2-6) ; therefore, it is likely
that the increased formation of LTB4 and the peptido-Us
observed here with GM-CSF-primed PMN and platelets
reflects, at least in part, the increased formation ofLTA4 by
GM-CSF--primed PMN and the transfer of LTA4 to platelets
for LTC4 production . The levels of LXB4 and its trans-
isomers were also increased in the presence ofplatelets, sug-
gesting that multiple biosynthetic routes may contribute to
the formation oflipoxins during the interactions of platelets
with GM-CSF-primed PMN .
Addition of thrombin (0.1 U/ml) to co-incubations con-
sisting ofGM-CSF-primed PMN and platelets led to an in-
crease in LXA4 and a decrease in the amounts of peptido-
LTs, while the level of LTBs was similar in both settings . For
purposes of comparison, the relationship between LXs and
"'1 Isolated PMN (30 x 106/ml) were incubated for 90 min at 37°C in the presence or $absence of GM-CSFrh (200 pM) . Next, aliquots (0 .5
ml) of each cell suspension were combined with 0.5 ml aliquots of isolated platelet suspensions (3 x 109/ml) . Cell ratios were approximately 1 :100
(PMN/platelet) in 1 ml . The suspensions were exposed to either A23187 (0.1 uM), FMLP (10-7 M), or FMLP (10-7 M) in combination with thrombin
(0 .1 U/ml). w,LTB 4 denotes [20-OH-LTB4 + 20-COOH-LTB4] and t-LX denotes the two coeluting all-trans-isomers of LXA4 and LXB4 , respec-
tively (see reference 13) . The incubations (20 min at 37°C) were terminated and analyzed by RP-HPLC as described in Materials and Methods .
Results are expressed in nanograms/incubation; mean ± SE of three separate experiments .
5 Products not detected.
Table 1 . GM-CSFrhprimed Human PMN Co-incubations with Platelets : Formation of Lipoxins and Leukotrienes
Incubation t-LXB4 LXB4 t-LXA4 LXA4 LTC4 LTD4 LTE4 w;LTB4 LTB4
GM-CSF-primed PMN'
+(FMLP10-7 M) 11.4±2 .9 7.9±2 .8 14.2±3 .3 14.1±5 .9 -5 -5 -5 51.7±4.5 13.8±3 .5
PMN± and platelets
(FMLP + thrombin) 21.0 ± 1 .5 24 .1 ± 1 .7 17.5 ± 3 .2 18 .6 ± 4 .5 52 .3 ± 8.1 28 .7 ± 8 .7 15.7 ± 7 .9 60.3 ± 7 .3 6 .2 t 2 .1
GM-CSF-primed PMN'
and platelets (FMLP) 103.7 ± 58.4 54 .0 ± 8 .4 26.7 ± 3 .1 22 .9 ± 6 .7 47.5 t 7.2 54 .7 ± 34 .2 13.0 ± 5 .3 77 .7 ± 11 .1 10 .5 t 4 .4
GM-CSF-primed PMN'
and platelets (FMLP
+ thrombin) 76.3 ± 30 .9 35 .5 ± 4 .6 23 .5 ± 4 .8 29 .6 t 7 .8 37.6 t 8 .0 21 .6 ± 5 .1 13.5 t 5 .7 75 .6 ± 12 .7 12 .2 ± 3 .0
GM-CSF-primed PMN'
and platelets (A2s18r,
10 -7 M) 134.1 t 74.3 100.7±26 .3 45.2±5 .5 46.2± 12.4 88.3±36 .2 34.5±9.6 21.5±9 .0 127.7±35 .6 21.3±8 .9LTs was determined for platelets co-incubated with PMN
stimulated with FMLP (10-7 M) and thrombin (0.1 U) in
the absence of the cytokine. In this case, both lipoxins and
leukotrienes were generated with LTC4 (which can be de-
rived from platelets; references 5, 6) and w-oxidation prod-
ucts ofLTB4 ) (formed byPMN; references 9, 10) registered
as the dominant products. GM-CSF-primedPMN coincubated
with platelets also generated lipoxins and LTs when exposed
to ionophore (A23187, 10 -7 M) (Table 1 ; last row) . Unlike
the other stimuli examined, the ionophore does not interact
with specific receptors and therefore may provide an index
ofthe biosynthetic potential ofthese cells to generate individual
lipoxygenase products during the interaction of GM-CSF-
primed PMN with platelets . Together these results indicate
that, during coincubation conditions (i.e., cell-cell interac-
tions) with GM-CSF-primed PMN, lipoxins are generated
in the range of amounts similar to that observed for individual
leukotrienes when cells are exposed to physiologically rele-
vant stimuli .
Next, we evaluated the role of cell ratio in receptor-mediated
formation of lipoxygenase products during coinincubation
of both PMN-platelets (Fig . 1, left) and GM-CSF-primed
PMN-platelets (Fig. 1, right). Upon exposure to thrombin
(0.1 U) and FMLP (10 -7 M), the levels of LTBs (E LTB4,
w-OH-LTB4, and 20-COON-LTB4) and lipoxins (E LXA4,
LXB4, and their all trans-isomers) were generated in excess
of the amounts ofpeptido-LTs. The levels ofpeptido-LTs did
not approach those observed for either theLXs or LTBs until
the platelet count exceeded -10 per PMN . At the cell ratio
of 1:10, the increase in peptido-LTs appears to follow a
reciprocal decrement in the levels ofMs . Since LTA4 is the
common precursor to both LTB4 and LTC4, it appears that
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Figure 1 .
￿
Formation oflipoxins and leukotrienesby PMN-platelet coin-
cubations stimulated with FMLP and thrombin : effect of cell ratio and
comparison with GM-CSF-primed PMN . (Left) PMN (15x 106 cells)
were co-incubated with autologous platelets in 1 ml and stimulated with
FMLP (10-7 M) and thrombin (0.1 U/ml) for 20 min at 37°C . (Right)
shows similar co-incubations where PMN were exposed to GM-CSFrh
(90 min, 37°C) before coincubations . Products were extracted and quanti-
tatedby combinedED-UVHPLC in two separate RP-HPLC systems (see
Materials and Methods). LTBs denotes the sum ofLTB4, 20-COON-LTB4
and 20-OH-LTB4, LXs are the sum ofLXA4 , LXB4, and their all-trans-
isomers and Us represents the sum of LTC4, LTD 4 , and LTE4 . The results
are representative of three separate experiments .
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metabolism . A similar reciprocal relationship between LTB4
and LTC4 has been established with suspensions of platelets
and granulocytes stimulated with ionophore A23187 (6) .
Coincubations of platelets with GM-CSF-primed PMN
generated higher levels of lipoxins (Fig. 1, tight) when ex-
posed to FMLP (10-7M) and thrombin (0.1 U) than coin-
cubations with PMN that were not primed with GM-CSF .
At cell ratios of 1:100(PMN platelets), the levels of lipoxins
exceeded those ofeither the LTBs or peptido-LTs. This finding
together with previous observations (7, 8) suggests that,
during the coincubation of GM-CSF-primed PMN and
platelets, several transcellular biosynthetic routesmay be oper-
ative to contribute to the production of lipoxins.
Co-incubation of -1 1CJarachidonate-labeled Platelets and Un-
labeled Neutrophils. During coincubations stimulated with
ionophore (An187), platelet-derived arachidonate can serve as
a precursor for PMN-derived LTB4 and 5-HETE (2), and
platelets can convert exogenous LTA4 to lipoxins (7, 8) as
well as peptido-LTs (5, 6) . To determine if these two biosyn-
thetic routes are operative during receptor-mediated eicosa-
noid formation by cell-cell interactions, labeled platelets were
co-incubated with bothPMN and GM-CSF-primed PMN
and the lipoxygenase products were analyzed for the content
of [1-14C] .
Representative radiochromatograms of mono-HETEs
obtained after stimulation of co-incubation with FMLP
(10 -7 M) and thrombin (0.1 U) are given in Fig. 2 . Both
5-HETE and 15-HETE carried [1-14C] platelet-derived radio-
label . These results illustrate that, after incubation with
thrombin, platelets release [1-14C]arachidonate, which was




RP-HPLC profile of [1 14C]-labeled mono-HETEs from co-
incubation of unlabeledPMN with [1-14C]arachidonate-labeled platelets
exposed toFMLP and thrombin . Isolated platelets were labeled (2) with
[1- 14C]-arachidonate, washed two times and incubated with autologous
PMN (1:100, PMN/platelets) in 1 ml PBS with 15 x 10 6 PMN . (Left)
Co-incubations were exposed to FMLP (10 -6 M) and thrombin (0.1
U/ml) for 20 min at 37°C . (Right) : PMN were primed with GM-CSFrh
(200 pM, 90 min, 37°C) before co-incubation with labeled platelets and
addition ofFMLP (10-6M) and thrombin (0 .1 U/ml) . Products were ex-
tracted and chromatographed with McOH/H20/acetic acid (75:25 :0.01,
vol/vol/vol) as the mobile phase. Arrows denote co-chromatography of
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RP-HPLC profiles of [1-14C]-labeled peptido-Us from co-
incubation of unlabeled PMN with [1-14C]arachidonate-labeled platelets
exposed to FMLP and thrombin . (Top) Co-incubations were exposed to
FMLP (10 -7 M) and thrombin (0.1 U/ml) for 20 min at 37 °C. (Bottom)
PMN were primed with GM-CSFrh (200 pM, 90 min at 37°C) before
co-incubation with labeled platelets and addition ofFMLP (10-7 M) and
thrombin (0 .1 U/ml). Here,McOH fractions fromincubations were chro-
matographed separately. Arrows denote retention times of synthetic stan-
dards. Results in each radiochromatogram are representative of three sepa-
rate experiments.
transformed by both the 5- and 15-lipoxygenase of FMLP-
activated PMN . With GM-CSF-primed PMN, a similar
HPLC profile was observed after addition of stimuli and an
enhanced level of [1-14C]-5-HETE was generated during the
co-incubations . These results are consistent with the demon-
strated enhancement in 5-lipoxygenase-derived products with
GM-CSF-primed PMN (9, 10) and provide further evidence
indicating that platelet-derived arachidonate (2) is an impor-
tant source of substrate forPMN lipoxygenase pathways. Fur-
ther analysis revealed that peptido-LTs from these incubation
conditions also carried [1- 14C] label (Fig. 3, top) . Since these
Human platelets (1.5 x 109 cells/ml) were incubated (20 min, 37°C) with LTA4 (20 W), human albumin (0.1%), and thrombin (0 .1 U/ml) .
Platelets were treated 30 min with DNCB or 3 minwith nitroprusside at 37 °C before addition of stimuli . Products were extracted and quantitated




products are generated from PMN-derived LTA4 (5, 6), it
appears that, during receptor-mediated cell-cell interaction,
platelet-derived [1- 14C]arachidonate is released and trans-
formed by the PMN 5-LO to [1-14C]-LTA4, which is then
transferred back to platelets for conversion to labeled peptido-
LTs . In contrast, withGM-CSFrh-primed PMN and labeled
platelets, labeled peptido-LTs were not generated in appreciable
amounts (Fig. 3, bottom), although unlabeled products were
formed . This observation suggests that labeled LTA4 may
have been diverted to other routes with the GM-CSF-primed
PMN (see Table 1 and Fig . 1) .
Along these lines, evidence for at least two transcellular
routes has been presented for lipoxin production: one involves
the transformation ofexogenous 15-HETE byhuman PMN
(13) and eosinophils (16), and the other involves the conver-
sion of LTA4 by human platelets (7, 8) . Lipoxins from these
incubation conditions also carried [1-14C] label, demon-
strating that platelet-derived arachidonate contributes to their
formation during cell-cell interactions initiated by receptor-
mediated mechanisms. However, since both [1-14C]15-HETE
and [1-14C]LTC4 (which can serve as an indicator of labeled
LTA4 formation by PMN) were detected, it was not possible
to conclude from the present data whichpathwaypredominates
in the formation of lipoxins during PMN-platelet interac-
tions. Nevertheless, the present findings provide evidence that
both PMN and platelets generate lipoxins by transcellular
routes . Agonist-induced generation oflipoxins by PMN ap-
pears to be enhanced by platelet-derived arachidonate, while
the platelet generation oflipoxins is dependent upon leukocyte-
derived LTA4 .
Conversion of LTA4 by Thrombin-activated Platelets .
￿
We
next determined the relationship between lipoxin and peptido-
LT production and assessed factors that alter their formation
by platelets (Table 2) . Thrombin-activated platelets generated
LTC4 + LTD4 in amounts greater than those ofLXA4 +
LXB4 from LTA4 . Conversion of LTA4 to lipoxins can in-
volve the platelet 12-LO (7, 8), while its conjugation to
LTC4 may involve a specific glutatione-S-transferree or plate-
let LTC4 synthetase (5, 6) . Depletion of GSH by treating
platelets with DNCB does not alter platelet aggregation or
Table 2 . Conversion ofLTA4 by Thrombin-activated Platelets: Relationship between Lipoxins and Peptidoleukotrienes
Incubations LXB4 LXA4 LTC4 LTD4
Platelets +
LTA4 + thrombin 0.1 U/ml 15.9 ± 3.7 21 .6 ± 7.9 111 .8 ± 13.7 24.1 ± 9.1
DNCB (100 PM) 55 .9 ± 6.4 23 .7 ± 9.9 22.1 ± 6.2 21.0 ± 6.6
DNCB (500 AM) 149.3 ± 13 .0 19 .3 ± 7.6 21 .0 ± 11.0 24.8 ± 8.4
Nitroprusside (10 AM) 31 .7 ± 6.0 30.0 ± 1 .8 14.5 ± 8.1 16.8 ± 5.3secretion (17), but enhances 12-lipoxygenase activity (18) .
Platelets treated with DNCB blocked the formation ofLTC4
and enhanced LXB4 but not LXA4 when compared with
untreated cells (Table 2) . The enzymatic generation ofLTC4
by platelets appears to be unlike that of macrophages, where
DNCB does not inhibit LTC4 formation by LTC4 synthe-
tase (19) . Nitroprusside-treated platelets gave elevated levels
of both LXA4 and LXB4 but generated less LTC4 . Since
nitroprusside (10 P,M) stimulates cGMP, inhibits Cal+ mobil-
ization, and blocks platelet aggregation (20), its ability to
divert the fate of LTA4, in favor of lipoxin production by
platelets (Table 2), may be related to the vasodilatory actions
of nitroprusside, since peptido-LTs are potent vasoconstrictors.
Thus, the levels of both lipoxins and peptido-Us generated
by platelets may be altered by drugs that influence the glu-
tathione status of platelets.
Countenregulatory actions oflipoxins have been documented
in renal microcirculation, where LXA4 stimulates vasodila-
tion and antagonizes the vasoconstrictive activity of LTD4
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